News Archives

News Archives

Avivagen Announces First Purchase Orders of OxC-beta™ Livestock in Mexico

Ottawa, ON /Business Wire/ March 25, 2020 / – Avivagen Inc. (TSXV:VIV) “Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, is pleased to announce its first purchase orders of OxC-beta™ Livestock in …Read More

Avivagen Inc. to Issue Shares in lieu of Annual Maintenance Fee

Ottawa, ON /Business Wire/ March 23, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that it has opted to issue common shares to satisfy $107,560 owing to the holders of 10% secured debentures issued by Avivagen on March 28, 2019 and April 9, 2019 on account of an annual maintenance fee owing to …Read More

Avivagen Accelerates Plans for Commercial Launch of its OxC-Beta™ Technology for Human Use in Response to COVID-19 Pandemic

Ottawa, ON / Business Wire / March 17, 2020 / – Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products that safely support immune function and dampen inflammation, thereby supporting general health and well-being, announces today that it is accelerating its plans for commercial launch of its OxC-Beta product as …Read More

Zacks Small Cap Research Analyist Note

Zacks Small Cap Research has published a new analyst note. On February 24, 2020, Avivagen, Inc. (VIVXF) announced positive and statistically significant results from its New Zealand dairy trial showing that OxC-beta™ has an effect against subclinical mastitis. There was a 13.9% rate of resolution of bacterial infection in cows fed feed containing OxC-beta compared …Read More

Avivagen Announces TSX Venture Exchange Approval for Extension of Warrants

Ottawa, ON /Business Wire/ March 10, 2020/ – Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely support immune function, promote general health and performance, announces that it has received approval by the TSX Venture Exchange to extend …Read More

BioPub Webinar Replay – Avivagen: Farming for the Future

On March 6th, 2020, Avivagen CEO Kym Anthony and Executive VP of Business Development and Product Innovation, James Nickerson, appeared on BioPub.  The interview was entitled “Avivagen: Farming for the Future”. It’s like a domino – each time you get somebody new using the product it makes it easier in that market to use more …Read More